Abstract Number: PB1022
Meeting: ISTH 2021 Congress
Background: Cardiovascular diseases are the leading cause of death worldwide, taking an estimated of 17.9 million lives each year, making their study pivotal in the medical field. Platelets are very important in thrombosis, hemorrhage, and inflammation and play a critical role in cardiovascular diseases. TREM-like transcript 1 (TLT-1), a pro-thrombotic membrane protein exclusive to platelets, has been linked to irregularities in clot formation especially in atherosclerosis and sepsis. Previous work demonstrated that activated platelets release a soluble form of TLT-1 (sTLT-1) found in serum but not in the plasma of healthy individuals.
Aims: 1) Evaluate if ADAMS17 is the main protease that releases TLT-1;
2) Determine if sTLT-1 can be used as marker for disease severity in patients with Cardiovascular Diseases.
Methods: We used western blotting and protease inhibitors to evaluate sTLT-1 release. Soluble TLT-1 was measured retrospectively by ELISA in plasma samples from patients that are in the Preventing Events of Angiotensin Converting Enzyme (PEACE) study. We used the program “R” and SPSS to evaluate the statistical relevance of the work.
Results: Figure 1 demonstrates that ADAMS 10 and 17 are only partly responsible for sTLT-1 release. Table 1 shows the analysis of sTLT-1 levels at baseline (day 1) samples. The analysis revealed several significant associations. Including increased sTLT-1 levels in patients that experienced arrythmia (p=0.007), however, lower levels of sTLT-1 were associated with those patients that underwent percutaneous intervention (p=0.03), had their left ventricular function qualitatively abnormal (QUALABS; p=0.008), or experienced unstable angina (p=0.043). There was not, however, any association with the primary outcomes of CV death (p=0.21) or other death (p=0.81). Interestingly, those patients that used cigarettes had on average significantly lower levels of sTLT-1(p=0.00012). Multivariant analysis revealed that QUALABS accounted for the raised levels of sTLT-1.
Conclusions: Surprisingly, TLT-1 /sTLT-1 may be a protective for QUALABS
To cite this abstract in AMA style:Bayron Z, Branfield S, Menendez J, Nieves B, Ospina L, Maldonado G, Hunter R, Valance Washington A, M Melendez L, M Cantres Y. Soluble Triggering Receptor Expressed on Myeloid Cells Like Transcript-1 (sTLT-1) as a Biomarker for Stable Cardiovascular Diseases [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/soluble-triggering-receptor-expressed-on-myeloid-cells-like-transcript-1-stlt-1-as-a-biomarker-for-stable-cardiovascular-diseases/. Accessed March 25, 2023.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/soluble-triggering-receptor-expressed-on-myeloid-cells-like-transcript-1-stlt-1-as-a-biomarker-for-stable-cardiovascular-diseases/